Evidence map›Paper›PMID 42026640›Full record

ArticleGenome medicine2026

Beyond carrier frequency: a preliminary multicenter study of simultaneous couple-based comprehensive carrier screening for common and rare genetic disorders.

Bing Xiao, Hongqian Liu, Yu Sun, Xiaotian Su, Chinese Medical Doctor Association of Genetics Counselling Board, Xiaoxiao Xie, Zhengfeng Xu, Feng Ren, Ying Peng, Ling Hui and 25 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Bing Xiao *Department of Pediatric Endocrinology and Genetics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Room 801, Sci & Edu Bldg, 1665 Kong Jiang Road, Shanghai, 200092, China.
Hongqian Liu *Department of Medical Genetics, West China Second University Hospital, Sichuan University, Chengdu, China.
Yu SunDepartment of Pediatric Endocrinology and Genetics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Room 801, Sci & Edu Bldg, 1665 Kong Jiang Road, Shanghai, 200092, China.
Xiaotian SuDepartment of Pediatric Endocrinology and Genetics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Room 801, Sci & Edu Bldg, 1665 Kong Jiang Road, Shanghai, 200092, China.
Chinese Medical Doctor Association of Genetics Counselling Board
Xiaoxiao XieDepartment of Obstetrics and Gynecology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Zhengfeng XuDepartment of Prenatal Diagnosis, Women's Hospital of Nanjing Medical University, Nanjing Women and Children's Healthcare Hospital, Nanjing, China.
Feng RenDepartment of Laboratory Medicine, The Second Affiliated Hospital of Dalian Medical University, Liaoning, China.
Ying PengDepartment of Medical Genetics, Hunan Provincial Maternal and Child Health Care Hospital, Changsha, China.
Ling HuiMedical Genetics Center/Gansu Provincial Clinical Research Center for Birth Defects and Rare Diseases, Gansu Provincial Maternity and Child-care Hospital (Gansu Provincial Central Hospital), Lanzhou, Gansu, China.
Liangpu XuMedical Genetic Diagnosis and Therapy Center, Fujian Key Laboratory for Prenatal Diagnosis and Birth Defect, Fujian Maternity and Child Health Hospital College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fujian, China.
Chunhua ZhangDepartment of Medical Genetics, Yunnan Maternal and Child Health Hospital, Kunming, China.
Jie DuanDepartment of Obstetrics, Zhongnan Hospital of Wuhan University, Wuhan, China.
Juan ZhangDepartment of Assisted Reproductive Centre, The affiliated Zhuzhou Hospital Xiangya Medical College, Central South University, Zhuzhou, Hunan, China.
Juan LiMedical Laboratory Center, The First Hospital of Lanzhou University, Lanzhou, China.
Shuyuan XuePrenatal Diagnosis Center, Urumqi Maternal and Child Health Hospital, Urumqi, China.
Shixiu LiaoMedical Genetics Institute of Henan Province, Henan Provincial Key Laboratory of Genetic Diseases and Functional Genomics, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Ling LiuDepartment of Medical Genetic and Prenatal Diagnosis, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhuoshu ZhaoMaternal and Children's Health Research Institute, Shunde Women and Children's Hospital, Guangdong Medical University, Foshan, China.
Dejian YuanDepartment of Medical Genetics, Liuzhou Hospital of Guangzhou Women and Children's Medical Center, Liuzhou, China.
Juan QiuLaboratory of Prenatal Diagnosis, Longhua Maternity and Child Healthcare Hospital, Shenzhen, Guangzhou, China.
Fuqing ZhangDepartment of Reproductive Genetics, Women & Infants Hospital of Zhengzhou, Zhengzhou, China.
Yang HuangPrenatal Diagnosis Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Yingchun HaDepartment of Prenatal Diagnosis, Yinchuan Maternal and Child Health Care Hospital, Yinchuan, Ningxia, China.
Lei YuCentral Laboratory, Guiyang Maternal and Child Health Care Hospital, Guiyang, China.
Kai TangGenetic Eugenics Laboratory, Maternal and Child Health Hospital of Baoji, Baoji, China.
Xiaozhou LiTianjin Key Laboratory of Female Reproductive Health and Eugenics, Tianjin Medical University General Hospital, Tianjin, China.
Wei PanGuizhou Prenatal Diagnosis Center, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Jing ShuCenter for Reproductive Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Jiansheng ZhuMedical Genetics Center, Anhui Women and Children's Medical Center, Affiliated Maternity and Child Health Hospital of Anhui Medical University, Hefei, China.
Ling MengMedical Genetics and Prenatal Diagnosis Center, Bijie Maternal and Child Health Hospital, Bijie, Guizhou, China.
Chenming XuGenetics Center, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
Aiping MaoDepartment of Research and Development, Berry Genomics Corporation, Beijing, China.
Nannan YanDepartment of Medical Product and Support, Berry Genomics Corporation, Beijing, China.
Yongguo YuDepartment of Pediatric Endocrinology and Genetics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Room 801, Sci & Edu Bldg, 1665 Kong Jiang Road, Shanghai, 200092, China. yuyongguo@shsmu.edu.cn.

Funding

National Key Research and Development Program of China No. 2022YFC2703400National Natural Science Foundation of China No. 82271904 and 82070914Natural Science Foundation of Shanghai Municipality 23ZR1452700
6 · The paper itself

Abstract

backgroundCurrently, the American College of Medical Genetics and Genomics (ACMG) carrier screening (CS) guidelines do not recommend routinely screening for conditions with carrier frequencies ≤ 1:200. Advances in DNA sequencing and declining costs, alongside growing awareness, make it increasingly feasible to expand CS to cover a broader spectrum of conditions. We aimed to design a CS panel regardless of carrier frequency to evaluate its utility in less common disease.

methodsWe developed a large CS panel through gene curation, phenotypic severity evaluation, independent of carrier frequency. A cohort of 2010 couples across 24 Chinese cities underwent couple-based simultaneous screening. Gene carrier rate (GCR) was calculated, with subsequent assessment of at-risk couple rate (ACR) across varying GCR thresholds.

resultsThe results obtained from testing 1736 genes were presented. Among 2010 couples undergoing CS, 106 were identified as having an increased risk of offspring with at least one genetic condition. The initial ACR is 5.3% (106/2010). After excluding couples not carrying high-risk CFTR variants based on the ACMG-recommended 100-variant panel for CFTR, the adjusted ACR was 5.2% (105/2010). Furthermore, after excluding GJB2: c.109 G > A and HFE, the adjusted ACR decreased to 2.2% (45/2,010). Fifty genes with a GCR ≥ 1/200 were identified through individual carrier analysis that were absent from the ACMG Tier 3 list. Setting a GCR ≥ 1/200 threshold would fail to detect 14 high-risk couples associated with 16 rare conditions: two couples carried pathogenic variants linked to two rare conditions each. Notably, 53.3% of identified high-risk couples would remain undetected under ACMG Tier 3-recommended conditions, with the majority of missed conditions representing rare yet severe disorders. The simultaneous couple-screening model maintained manageable ACR while resolving all reproductive concerns in a single phase, thereby reducing genetic counseling demands compared to sequential approaches. This methodology also minimized false-positive interpretations through integrated variant analysis.

conclusionsThis study obtained preliminary Chinese population-specific GCR for both common and rare recessive conditions, providing a foundation for future CS panel optimization. Couples at risk of having a child with rare conditions are often undetectable using conventional CS paradigms that set GCR levels at ≥ 1/200 thresholds, emphasizing the need to expand beyond ACMG Tier 3 standards to address rare severe genetic disorders. For large CS panels, simultaneous couple-based screening is an effective strategy.

Indexed as

Genetic Carrier ScreeningGenetic Diseases, InbornGenetic TestingHeterozygoteRare DiseasesFemaleGene FrequencyHumansMaleChinese populationComprehensive carrier screeningRare disease

Identifiers

PMID42026640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.